Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled study of 50561 tablets in mild to moderate Alzheimer's disease with psychiatric symptoms
CTR20264161Phase 2Active
- Sponsor
- Beijing Zhuokai Biotechnology
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JK 50561 in Alzheimer's disease (AD), sponsored by Beijing Zhuokai Biotechnology. Started Nov 2026; status: active.
02
Drugs
JK 50561
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20264161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264161.